Analyst Expectations for Regeneron Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has received a mix of bullish and indifferent ratings from analysts in the last quarter. The company has an average 12-month price target of $901.36, which has increased by 3.11% over the past month.

September 21, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received a mix of bullish and indifferent ratings from analysts, with an average 12-month price target of $901.36.
The mixed analyst ratings indicate uncertainty about the company's future performance. However, the increase in the average price target over the past month suggests a positive outlook. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100